Further analysis found that the serum miR-9-5p levels were significantly higher in the HER2-positive breast cancer patients compared to the HER2-negative patients, indicating that serum miR-9-5p levels may distinguish the HER2-positive subtype of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.